Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study Publisher Pubmed



Aryanian Z^{1, 2} ; Balighi K^{1, 3} ; Daneshpazhooh M^{1, 3} ; Karamshahi E¹ ; Hatami P¹ ; Goodarzi A⁴ ; Tajalli M⁵ ; Vance TM⁶ Show Affiliations
Source: International Immunopharmacology Published:2021

Abstract

Background: Pemphigus is an autoimmune disease that is challenging to treat and has few available therapeutic options. Recently, several studies have demonstrated that rituximab may be an efficacious first-line treatment in newest guidelines. Aim: To compare the side effect profiles of rituximab administered after a course of immunosuppressant agents versus as a first-line therapy and evaluate the impact of patient characteristics and disease severity indices on occurrence of adverse effects. Methods: A retrospective cross-sectional study was conducted on 999 patients with pemphigus vulgaris who received rituximab either as a first-line treatment or after conventional adjuvant therapies. The occurrence of partial or complete remission as well as the incidence of drug-related adverse effects were evaluated and compared between the two groups. Results: Smoking, pulmonary comorbidity, and mucocutaneous phenotype were associated with an increased risk of developing infectious complications by 12.49, 5.79, and 2.37 fold, respectively. These associations were more prominent among those who received rituximab after immunosuppressant agents. Conclusions: Early use of rituximab benefits pemphigus patients, especially those with a mucocutaneous phenotype, pulmonary comorbidity, or history of smoking, and reduces their risk of infectious adverse events. © 2021 Elsevier B.V.